Will Strength in Biotechnology Unit Continue to Drive Danaher's Growth?

Key Takeaways Biotechnology segment at DHR posted 6.5% core revenue growth in Q3 2025 on sustained bioprocessing momentum.Strong consumables and mAbs demand drove bioprocessing orders higher for a ninth quarter at Danaher.Despite equipment demand headwinds, Danaher expects Biotechnology core revenues to rise about 5% in Q4 2025.Danaher Corporation (DHR) has been benefiting from strength in its Biotechnology segment. In the third quarter of 2025, the segment’s core revenues increased 6.5% on a year-over-year ...